Side-by-side · Research reference

KPVvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongAUTO-DRAFTED13/39 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

KPV

α-MSH C-terminal · Anti-inflammatory

200–500 mcgDaily doseDalle-Pang 2024

AnimalEvidence levelDalle-Pang 2024

HoursHalf-life (est)

SQ / oral / topical · Local · Daily or 2-3×/week

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

KPV

Vesugen

Primary target

Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

No melanocortin receptor binding

Not applicable — does not operate via hormone axis

Origin

Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

KPV

Vesugen

Standard dose

200–500 mcg / day SQ or oralDalle-Pang 2024

—

Frequency

Daily or 2–3× per week

Not specified in available literature

Lower / starter dose

100 mcg / day

—

Evidence basis

Animal-strong + emerging clinical data in IBDDalle-Pang 2024

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration

4–8 weeks per cycle

Case series report treatment courses in elderly arterial insufficiency

Reconstitution

Bacteriostatic water (SQ form)

—

Timing

No specific time; often taken with / before meals (oral)

—

Half-life

Hours (estimated; rapid tissue uptake)

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

04Side Effects & Safety

Parameter

KPV

Vesugen

Injection site reaction

Mild irritation

—

GI symptoms

Rare nausea (oral form)

—

Pigmentation

None (unlike full α-MSH)Dalle-Pang 2024

—

Long-term safety

Limited human data

Unknown — no long-term RCT data

Pregnancy / OB

Avoid — insufficient data

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

KPV

·Pregnancy / breastfeeding

Vesugen

—

Relative Contraindications

KPV

·Active autoimmune disease (theoretical)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

KPV

Vesugen

1. Reconstitution

Add 1 mL bacteriostatic water to vial per labelling.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Form

SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Morning preferred; oral form taken with / before meals.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Needle

29–31G insulin syringe (SQ form).

—

06Stack Synergy

KPV

+ BPC-157

Strong

View BPC-157 →

KPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.

KPV: 200–500 mcg oral · daily
BPC-157: 250–500 mcg oral or SQ · daily
Primary benefit: Combined anti-inflammation + mucosal repair for gut conditions

Dalle-Pang 2024 Sikiric 2018

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)